To be sure, it is good news, for people who do get sick. And to be clear, I continue to think larger studies of the Merck v. Pfizer candidates, when compared, will yield more closely-similar / approximate outcomes data (we may be seeing the law of small numbers here) -- but let's give the minority view its say. The bit, then from The New York Times, just a few minutes ago:
. . .In the coming weeks, the F.D.A. may also authorize a similar pill from Pfizer that appears to be significantly more effective than Merck’s. Together, the arrival of the two easy-to-use treatments could provide a cushion against a resurgent virus.
The F.D.A. advisory panel, a group of experts on antimicrobial drugs, recommended that Merck’s treatment be authorized for people with Covid who are at high risk of becoming severely ill. That would most likely cover tens of millions of Americans who are older or have medical conditions such as obesity, diabetes or heart disease.
But the committee’s close vote reflected doubts about the pill’s effectiveness and concerns that it could cause reproductive harm. “The efficacy of this product is not overwhelmingly good,” said Dr. David Hardy, an infectious disease physician in Los Angeles who voted to recommend the drug. Still, he voted to recommend the drug. . . .
Onward, smiling -- to grill a likely final Chicago aged rib-eye of the year 2021. . . since the weather is cooperating. Be excellent to one another.
नमस्ते
No comments:
Post a Comment